Health
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3 | NEJM – nejm.org
Correspondence from The New England Journal of Medicine — SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
We conducted a global, randomized, placebo-controlled, phase 123 pivotal trial in which two 30-g doses of BNT162b2 (PfizerBioNTech) were administered 21 days apart (ClinicalTrials.gov number, NCT04368728). These doses of vaccine had mainly low-grade side…
Continue Reading
-
Business20 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business19 hours ago5 things to watch on the ASX 200 on Monday 7 April 2025
-
General6 hours agoThe right-wing stupidity repeating Liberal Party history
-
General6 hours agoDefence minister won’t say if security agencies or Trump administration pushed for Darwin Port backflip